A tunable Caco-2/HT29-MTX co-culture model mimicking variable permeabilities of the human intestine obtained by an original seeding procedure.
Standard monoculture models utilizing Caco-2 monolayers were extensively used to mimic the permeability of the human intestinal barrier. However, they exhibit numerous limitations such as the lack of mucus layer, an overestimation of the P-gp-mediated efflux and a low paracellular permeability. Here, we suggest a new procedure to set up an in vitro model of intestinal barrier to adjust gradually the properties of the absorption barrier. Mucin-secreting HT29-MTX cells were added to Caco-2 absorptive cells in a Transwell® at different time intervals. Effects of seeding day of HT29-MTX on the paracellular permeability of lucifer yellow (LY) and on the P-gp-mediated efflux of rhodamine 123 were investigated. Apparent permeability of the rhodamine 123 in the secretory direction was highly dependent on the seeding day of goblet cells. Transepithelial electrical resistance values and LY transport across the co-cultures in the apical-to-basolateral direction were intermediary between single Caco-2 and HT29-MTX models. Early seeding days of HT29-MTX allowed increasing the fraction of goblet cells in the co-culture. Co-culture permeability was unchanged between 21 and 30 days after Caco-2 seeding, corresponding to the period of use for Caco-2-based cell models. Thus, the HT29-MTX seeding day was a key factor to set up an in vitro intestinal model with tailor-made barrier properties in terms of P-gp expression and paracellular permeability.
Laboratory of Pharmaceutical Engineering, University of Franche-Comté, Besançon, France.
Arnaud
A
Béduneau
Laboratory of Pharmaceutical Engineering, University of Franche-Comté, Besançon, France.
Camille
C
Tempesta
Laboratory of Pharmaceutical Engineering, University of Franche-Comté, Besançon, France.
Stéphane
S
Fimbel
Laboratory of Pharmaceutical Engineering, University of Franche-Comté, Besançon, France.
Yann
Y
Pellequer
Gattefossé SAS, Saint-Priest Cedex, France.
Vincent
V
Jannin
Gattefossé SAS, Saint-Priest Cedex, France.
Frédéric
F
Demarne
Laboratory of Pharmaceutical Engineering, University of Franche-Comté, Besançon, France; Laboratory of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, Germany. Electronic address: alf.lamprecht@uni-bonn.de.
Alf
A
Lamprecht
D018435:ATP Binding Cassette Transporter, Subfamily B / Q000378:metabolism; D001692:Biological Transport; D018938:Caco-2 Cells; D002450:Cell Communication; D018929:Cell Culture Techniques; D018920:Coculture Techniques; D017097:Electric Impedance; D020397:Goblet Cells / Q000378:metabolism; D019073:HT29 Cells; D006801:Humans; D007408:Intestinal Absorption; D007413:Intestinal Mucosa / Q000378:metabolism*; D007419:Intestinal Secretions / Q000378:metabolism; D007546:Isoquinolines / Q000378:metabolism; D018613:Microscopy, Confocal; D009077:Mucins / Q000378:metabolism; D010539:Permeability; D020112:Rhodamine 123 / Q000378:metabolism; D013997:Time Factors
C513055:ABCB1 protein, human; D018435:ATP Binding Cassette Transporter, Subfamily B; D007546:Isoquinolines; D009077:Mucins; D020112:Rhodamine 123; C017475:lucifer yellow
Caco-2 cells; Drug absorption model; Goblet cells; In vitro intestinal barrier; Mucus; Seeding procedure